Publicaciones en las que colabora con Josep Tabernero Caturla (30)

2021

  1. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

2019

  1. A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 121, Núm. 5, pp. 378-383

2018

  1. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer

    British Journal of Cancer, Vol. 119, Núm. 12, pp. 1464-1470

2017

  1. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: An expert taskforce review

    Annals of Oncology, Vol. 28, Núm. 12, pp. 2943-2949

2016

  1. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    Annals of Oncology, Vol. 27, Núm. 8, pp. 1386-1422

2014

  1. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer

    Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 865-878

2013

  1. Fe de errores a «Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon»

    Revista Espanola de Patologia

2012

  1. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: A spanish cooperative group for the treatment of digestive tumors study

    Oncologist, Vol. 17, Núm. 7, pp. 947-955

  2. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Onkologie, Vol. 6, Núm. 2, pp. 96-103

  3. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Oncologist, Vol. 17, Núm. 1, pp. 15-25

  4. Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon

    Revista Espanola de Patologia

  5. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10

2011

  1. The diagnosis and management of gastric cancer: Expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010

    Annals of Oncology

  2. Treatment recommendations for metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 13, Núm. 3, pp. 162-178

2010

  1. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009.

    Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

2009

  1. Consensus on the treatment of pancreatic cancer in Spain

    Clinical and Translational Oncology, Vol. 11, Núm. 5, pp. 290-301

  2. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study

    Critical Reviews in Oncology/Hematology, Vol. 70, Núm. 2, pp. 134-144

  3. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008

    Annals of Oncology

2008

  1. Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study

    Acta Oncologica, Vol. 47, Núm. 2, pp. 286-292

  2. The diagnosis and management of rectal cancer: Expert discussion and recommendations derived from the 9th world congress on gastrointestinal cancer, Barcelona, 2007

    Annals of Oncology